Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.54 USD
-0.01 (-0.18%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $5.53 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Alimera Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 5 | 17 | 11 | 9 |
Receivables | 35 | 20 | 19 | 17 | 19 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 2 | 3 | 3 | 1 |
Other Current Assets | 4 | 3 | 4 | 4 | 3 |
Total Current Assets | 52 | 29 | 42 | 35 | 33 |
Net Property & Equipment | 2 | 3 | 3 | 2 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 1 | 1 |
Intangibles | 97 | 9 | 11 | 13 | 15 |
Deposits & Other Assets | 0 | 0 | 1 | 0 | 0 |
Total Assets | 154 | 43 | 59 | 51 | 50 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 25 | 0 | 0 | 0 |
Accounts Payable | 8 | 10 | 9 | 7 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 4 | 4 | 3 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 22 | 40 | 13 | 12 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 64 | 19 | 43 | 42 | 39 |
Non-Current Capital Leases | 0 | 0 | 0 | 1 | 0 |
Other Non-Current Liabilities | 21 | 5 | 5 | 4 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 107 | 63 | 61 | 59 | 55 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 19 | 19 | 19 | 30 |
Common Stock (Par) | 1 | 0 | 0 | 0 | 0 |
Capital Surplus | 462 | 378 | 377 | 366 | 350 |
Retained Earnings | -418 | -415 | -397 | -393 | -388 |
Other Equity | 2 | -3 | -2 | 0 | 3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 46 | -21 | -3 | -8 | -4 |
Total Liabilities & Shareholder's Equity | 154 | 43 | 59 | 51 | 50 |
Total Common Equity | 46 | -40 | -22 | -27 | -35 |
Shares Outstanding | 52.40 | 7.00 | 6.90 | 5.10 | 4.90 |
Book Value Per Share | 0.88 | -5.72 | -3.17 | -5.34 | -7.10 |
Fiscal Year End for Alimera Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11 | 14 | 12 | 8 | 19 |
Receivables | 37 | 34 | 35 | 34 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 2 | 2 | 2 | 1 |
Other Current Assets | 4 | 4 | 4 | 4 | 4 |
Total Current Assets | 55 | 54 | 52 | 48 | 46 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 92 | 94 | 97 | 102 | 105 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 150 | 152 | 154 | 154 | 155 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 10 | 8 | 6 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 10 | 13 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 21 | 22 | 18 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 70 | 69 | 64 | 64 | 64 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 22 | 21 | 23 | 30 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 112 | 112 | 107 | 105 | 109 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 75 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 465 | 463 | 462 | 462 | 387 |
Retained Earnings | -428 | -425 | -418 | -415 | -413 |
Other Equity | 1 | 2 | 2 | 1 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 39 | 41 | 46 | 49 | 46 |
Total Liabilities & Shareholder's Equity | 150 | 152 | 154 | 154 | 155 |
Total Common Equity | 39 | 41 | 46 | 49 | -29 |
Shares Outstanding | 52.30 | 52.30 | 52.40 | 52.40 | 8.80 |
Book Value Per Share | 0.74 | 0.78 | 0.88 | 0.93 | -3.24 |